A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Phase 2
Active, not recruiting
NCT03069378
| Condition | Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 41 participants |
|---|
| Interventions | Talimogene Laherparepvec (T-VEC), Pembrolizumab |
|---|
| Start date | Mar 3, 2017 |
|---|
| Completion date | Jul 22, 2025 |
|---|
| Results posted | Oct 29, 2025 |
|---|
Summary
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
Best Objective Response Rate
24 weeks · Participants
| Talimogene Laherparepvec (T-VEC) Administered With Pembrolizu | 13 Participants |
|---|
| Talimogene Laherparepvec (T-VEC) Administered With Pembrolizu | 13 Participants |
|---|
| Talimogene Laherparepvec (T-VEC) Administered With Pembrolizu | 14 Participants |
|---|
| Talimogene Laherparepvec (T-VEC) Administered With Pembrolizu | 1 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.